InvestorsObserver is giving Urogen Pharma Ltd (URGN) an Analyst Rating Rank of 59, meaning URGN is ranked higher by analysts than 59% of stocks. The average price target for URGN is $31 and analyst’s rate the stock as a Strong Buy.
Wall Street analysts are rating URGN a Strong Buy today. Find out what this means to you and get the rest of the rankings on URGN!